Kat Marie Alvarez, RN, MBA, on operator-led diligence, disciplined capital, and why not every good company is the right fit
Capital is everywhere in healthcare. Synergy is not.
For Kat Marie Alvarez, Founder and CEO of Katalyst & Co., investing is not about chasing market momentum. It is about backing companies that can operate inside the realities of regulated, risk-bearing healthcare environments. With more than 25 years across frontline nursing, payer leadership, and executive roles inside organisations responsible for millions of lives and billions in P&L, Kat approaches investment through a clinical operator’s lens. At Katalyst’s Venture Studio, capital is deployed quite selectively.
In this conversation, she explains what Katalyst looks for, what immediately disqualifies opportunities, and what founders should understand before reaching out.
Q
What types of healthcare companies are you actively looking to invest in?
A
We look for companies that solve real operational problems inside healthcare. Because Katalyst Health sits at the centre of our platform, we are constantly seeing where friction exists, whether that is in care coordination, member engagement, workforce efficiency, or compliance infrastructure.
The companies that stand out are those grounded in the realities of payer frameworks and regulatory constraints. We are interested in solutions that can function inside value-based or risk-bearing environments. We also look for leadership teams that understand healthcare is not just a technology problem. It is clinical, operational, and cultural at the same time.
If a company demonstrates that it understands how care is actually delivered and has built with that in mind, it earns our attention. We are not investing in hype cycles or the next big tech. We are investing in durability.
Q
When you are evaluating a potential investment, what immediately gives you pause or disqualifies an opportunity, particularly in today’s healthcare environment.
A
The fastest way for an opportunity to lose momentum with us is when growth assumptions are disconnected from operational feasibility. If a company cannot clearly explain how its model works inside existing payer structures or how it navigates compliance requirements, that is a red flag.
Another disqualifier is a lack of clarity around execution. We often ask founders to walk me through how their solution performs under pressure, when reimbursement shifts, when workforce strain increases, and when adoption is slower than projected. If the answer is overly polished and avoids those realities, it signals that the model may not have been tested deeply enough.
We also step back when incentives are misaligned. If a company’s revenue depends on utilisation patterns that conflict with value-based outcomes, that tension must be addressed. We invest where incentives and care quality are complimentary.
Q
You describe your diligence as operator-led. How is that different from a purely financial review?
A
A financial review evaluates projections, margins, and return scenarios. That is important, and we absolutely examine those elements. But operator-led diligence goes further. It asks whether the model can hold inside the day-to-day realities of healthcare delivery.
We look at how a company would perform under payer scrutiny. I think about how compliance teams would evaluate it, how clinical leaders would integrate it into workflow, and whether it adds complexity or reduces it.
We assess infrastructure to support scale, not just whether revenue can grow. That perspective often changes the conversation. Some opportunities look attractive financially but would struggle operationally. Our diligence is designed to surface that early, before capital is deployed. It is not a disqualifier. It is a barometer on what is needed post transaction and aids in formulating post transaction plan.
Q
Once Katalyst decides to invest, how do you add value beyond capital, and what does involvement typically look like after the deal closes?
A
When we allocate capital, we bring operational insight with it. That may involve refining the go-to-market strategy to align with payer dynamics, strengthening clinical integration, or pressure-testing expansion pacing.
Because Katalyst Health operates as our clinical core, we have visibility into what adoption looks like in real settings. That allows us to provide grounded feedback rather than abstract guidance. We can help companies anticipate friction points before they encounter them at scale.
In some cases, value comes from introducing disciplined sequencing, ensuring infrastructure keeps pace with growth. In others, it comes from connecting leadership teams to partners who understand risk-bearing environments. Our role is not to override founders. It is to strengthen their model so it performs consistently under real-world conditions.
Q
Before reaching out to Katalyst & Co., what should founders understand about how you evaluate opportunities and the kind of partnership you expect to build?
A
Founders should understand that we will evaluate their company through an execution lens. We are not only asking whether the market opportunity is large. We are asking whether the model works inside regulatory and operational constraints.
Clarity matters. Founders who can articulate where their solution fits in a care pathway, how it aligns with value-based incentives, and what assumptions underpin their growth tend to stand out. Transparency about challenges also builds credibility. No healthcare company scales without encountering friction. We respect leaders who acknowledge that.
Most importantly, alignment is critical. We invest where we believe we can add operational value, not just financial backing. If that partnership mindset exists from the beginning, the conversation becomes far more productive.
Q
Now that you’ve been clear about how you invest and what you look for, what kind of founders or opportunities are you hoping will reach out to you?
A
We want to attract founders who are building for longevity and have true commitment for solving the inherent challenges in healthcare. Healthcare rewards durability. It rewards leaders who understand that compliance, clinical integrity, and financial performance must coexist.
By being transparent about how we invest, we hope to create alignment before diligence even begins. When founders approach us knowing that we prioritise operational readiness and clinical accountability, the dialogue starts at a different level. It becomes less about selling a vision and more about evaluating fit.
Inbound flow improves when expectations are clear. We are selective by design, but for the right companies, those grounded in real healthcare realities, we can be a meaningful long-term partner and add tremendous value. Our engagement results speak for themselves.
